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Abstract
Background: The waiting interval after chemoradiotherapy (CRT) is an interesting therapeutic window to treat patients
with synchronous liver metastases (SLM) from rectal cancer.
Methods: A retrospective analysis was performed of 18 consecutive patients (M/F 10/8, age (range) 60 (51–75) years)
from five institutions who underwent liver resection of SLM during the waiting interval after CRT for rectal
adenocarcinoma.
Results: All patients underwent interval liver surgery for a median (range) of 4 (2–14) liver metastases. Metastases
involved a median (range) of 4 (1–7) liver segments. Median (range) time between end of CRT and liver surgery was 22
(6–45) days. Laparoscopic liver surgery was performed in 12 (67%) patients. No severe complications (Clavien-Dindo≥
3b) occurred after liver surgery. Median (range) length of hospital stay after liver surgery was 5 (1–10) days. All patients
subsequently underwent rectal resection at a median (range) of 10 (8–13) weeks after end of CRT. Median (IQR) time-
to-progression after liver surgery was 4.2 (2.8–9.2) months.
Conclusions: The waiting interval after neoadjuvant CRT is a valuable option to treat SLM from rectal cancer. More
data are necessary to confirm its oncological efficacy.
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Background
Patients with colorectal cancer develop liver metastases
in 60% of cases during the course of their disease. In
15–25% of patients with colorectal cancer liver metasta-
ses are present at time of initial diagnosis, i.e., synchron-
ous liver metastases [1]. In this group of patients, several
strategies have been proposed to manage both primary
and liver metastases. These strategies may be categorized
as either a delayed approach, sometimes also referred to
as staged approach, or a simultaneous (i.e., combined)
approach in which colorectal resection and liver surgery
are performed during a single anesthesia [2]. The
delayed approach may be further divided in a colon-first
or liver-first approach [3, 4] depending on which organ
is operated first. Which strategy to choose depends on
the presentation of the primary tumor and extent of liver
disease. Especially in advanced or borderline resectable
liver metastatic disease, it may be preferable to first
eradicate liver metastases after a preoperative course of
(conversion) chemotherapy.
A recent meta-analysis combining data on 18 studies
and 3605 patients with synchronous colorectal liver me-
tastasis did not demonstrate a clear statistical surgical out-
come or survival advantage of any of these three
approaches [5]. Meta-analysis of these non-randomized
trials is problematic, as a major selection bias exists. In-
deed, it has previously been found that patients undergo-
ing colon-first or simultaneous approach had less
advanced liver disease. Also, patients with rectal cancer
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represent only a small subgroup within this trial popula-
tion and it is unknown whether the same conclusions may
be drawn for these patients. The management of patients
with synchronous liver metastases from rectal cancer is
further complicated by the need for neoadjuvant chemora-
diotherapy in those cT3 +N0/+ cancers arising in the
lower two thirds of the rectum. Also, a simultaneous ap-
proach is generally not advocated for patients with simul-
taneous liver metastases from rectal cancer, owing to an
increased risk for postoperative complications [6, 7].
As there is a trend to increase the waiting interval up to
10 weeks after neoadjuvant chemoradiotherapy (CRT) for
rectal adenocarcinoma to optimize treatment response
[8], an interesting therapeutic window has opened up to
treat patients with synchronous liver metastases. Our aim
was to perform a multi-institutional analysis of patients
with rectal cancer who underwent interval laparoscopic
liver resection of synchronous colorectal liver metastases.
Methods
Between 2010 and 2015, 18 patients (M/F 10/8, age
(range) 60 (51–75) years) at 5 different Belgian institutions
(non-academic teaching hospital (n = 4) and academic
hospital (n = 1)) underwent liver surgery during the wait-
ing interval after CRT for rectal adenocarcinoma present-
ing with synchronous liver metastases.
Demographic, tumor-related, surgical procedure-related,
and outcome parameters were retrieved from this data-
base. Complications were registered and categorized ac-
cording to the Clavien-Dindo [9] and the Comprehensive
Comorbidity Index (CCI) [10].
Survival analysis was performed using the common
closing date for follow-up. Median (range) follow-up
after liver surgery was 20.5 (3.6–63.1) months. Time-to-
progression and overall survival was calculated using
Kaplan-Meier survival plots.
Ethical approval was obtained from the institution co-
ordinating the retrospective study (Belgian registration
No: B243201524173).
Results
All patients underwent interval liver surgery for a median
(range) of 4 (2–14) liver metastases. Liver metastases in-
volved a median (range) of 4 (1–7) liver segments. Portal
vein embolization was performed prior to liver resection
in 5 patients. Median (range) time (days) between last ir-
radiation and liver surgery was 22 (6–45) days. Laparo-
scopic liver surgery was performed in 12 (67%) patients
(10 resections, 2 radiofrequency ablations). Types of liver
resections are summarized in Table 1. Median (range) of
operating time was 186 (100–450) min.
Five patients developed a postoperative complication
after liver surgery. One patient developed biliary fistula re-
quiring surgical intervention under general anesthesia
(Clavien-Dindo ≥ 3b). Median (range) CCI was 0 (0–33.7).
Median (range) length of hospital stay after liver surgery
was 5 (1–10) days. All patients subsequently underwent
rectal resection without treatment delay at a median
(range) of 10 (8–13) weeks after the last irradiation. Rectal
resections consisted of two partial mesorectal excisions
(PME), 14 total mesorectal excisions (TME), and two
abdomino-perineal rectal amputations (APR). Rectal re-
sections were performed laparoscopically in 15 patients.
Ten patients developed tumor progression during follow-
up. Median (interquartile range) time-to-progression after
liver surgery was 4.2 (2.8–9.2) months. The liver was one of
the sites of tumor progression in 7/10 patients. Three pa-
tients died during follow-up. The median overall survival in
our cohort could not be calculated because after a median
follow-up time of 20.5 (3.6–63.1) months, more than 50%
of patients were still alive.
Discussion
To our knowledge, this is the first report of using the
waiting interval after CRT for resection of synchronous
liver metastases from rectal cancer. In addition, we show
that by using a laparoscopic approach for both liver and
rectal surgery, this may be achieved with minimal mor-
bidity and short hospital stay.
Insufficient evidence is available to guide the precise
extent of liver resection that can be safely undertaken in
combination with colorectal resection [11]. “Delayed” re-
sections are favored over simultaneous resections in pa-
tients with synchronous colorectal liver metastasis when
extensive liver disease (≥3 segments) [12]. This may be
one of many other reasons why the simultaneous ap-
proach has not found many enthusiasts. In addition lon-
ger operating times (>300 min), the increased technicity
of both liver and rectal resections, practical issues re-
garding operation room setup (a fortiori for laparoscopic
surgery) [2], and the high postoperative morbidity for
major liver resections [13] have limited the widespread
Table 1 Type of liver resection with location of liver metastatic
disease for minor hepatectomies
Type of liver resection
(Brisbane-classification)
Segments N patients
Right hemihepatectomy 5–8 6
Extended left hemihepatectomy 1–5, 8 1
(Bi)segmentectomy Pt 2 (2, 3)
Pt 11 (7)
Pt 12 (8)
Pt 16 (2, 4, 6)
Pt 17 (6–8)
5
Metastasectomy Pt 4 (6, 8),
Pt 8 (2–5, 7, 8),
Pt 13 (3–5, 7),
Pt 14 (7, 8)
4
Radiofrequency ablation Pt 7 (6, 8)Pt 10 (6, 7) 2
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adoption of the simultaneous approach especially for
treatment of synchronous liver metastatic disease from
rectal adenocarcinoma.
Simultaneous resection for rectal cancer might be asso-
ciated with more postoperative complications [6]. More-
over, oncological concerns have been expressed against
the simultaneous approach. LiverMetSurvey analysis
showed significantly worse overall and progression-free
survival rates at 3 years for the simultaneous approach
compared to the delayed group [14].
Therefore, our approach of using the waiting interval
for liver resection is extremely tempting as it may pro-
vide the solution to avoid an increased risk of complica-
tions and mortality when performing liver and rectal
resection during the same anesthesia. The interval ap-
proach is a variation of the delayed approach, without
lengthening the overall treatment duration. Interestingly,
despite the fact that all participating centers in the retro-
spective cohort share a parenchyma-sparing approach to
liver surgery for colorectal liver metastase, the majority
of patients underwent an extensive hepatic resection. It
is however known that patients presenting with syn-
chronous liver metastases have more advanced disease
(i.e., more metastases and more often bilobarly distrib-
uted metastases) at presentation [15]. This fact may at
least partially explain why most of the patients in this
cohort underwent extensive resections. Also, some bias
may exist as in the participating centers for patients with
limited metastatic disease eligible for a limited number
of (laparoscopic) liver-sparing resections a simultaneous
approach would have been favored. We are aware that
complications after liver surgery (especially major liver
resection) are not uncommon. Review of the literature
learns that complications occur at a frequency of 5–15%
for minor laparoscopic resections to up to 50% for major
open resections. It is therefore the policy of participating
centers in patients with multiple or large liver metasta-
ses or where a major liver resection is anticipated for R0
resection, to start with upfront chemotherapy in order to
obtain a good hepatic and extra-hepatic systemic control.
Following this chemotherapy, a radiological re-evaluation
is executed. In case of an objective radiological response,
chemoradiotherapy may be initiated and liver resection
can be performed during the waiting interval. In those
cases where the planned liver resection would be a trisec-
tionectomy or a procedure necessitating vascular or biliary
reconstruction, we would not perform liver resection dur-
ing the waiting interval after chemoradiotherapy, but ra-
ther preceding chemoradiotherapy.
To our surprise, median time to tumor progression in
our cohort was only 4.2 months. The liver was among
the primary site of tumor progression in 7 out of 10
patients. This finding may reflect the advanced stage of
disease at diagnosis or at least its aggressive tumor
biology. A similar conclusion was drawn recently by
Welsh et al. [16] that patients with simultaneous colo-
rectal liver metastases selected for a liver-first approach
had more advanced disease and a poorer prognosis.
These patients had a inferior cumulative disease-free
survival than those patients undergoing a classical ap-
proach, a difference negated by matching preoperative
Basingstoke Predictive Index [16].
Indeed, as an example of advanced disease in our co-
hort, resection specimens of eight patients revealed at
best a yN2a nodal status after CRT. Nevertheless, after a
median follow-time of 20.5 months, the median overall
survival could not be estimated. Another explanation for
the early tumor progression seen in our cohort may be
that selection of patients with excellent prognosis may
be more difficult in patients with synchronous liver me-
tastases, especially when the interval approach is used.
We are aware of some shortcomings of our study. All
together, this remains a retrospective study with rela-
tively small sample size. The small sample size precludes
in-depth analysis of other prognostic factors (e.g., pre-
operative CEA levels) to explain the early tumor progres-
sion seen in our series. In order to increase overall sample
size, we have merged experience of different centers.
Thereby, we have showed that this approach is not ex-
clusive to just one center (single-center experience) but
has succesfully been used in different centers in selected
cases with low morbidity both for a laparoscopic and
open approach. Long-term prospective studies with
overall and disease-free survival are needed to confirm its
oncological non-inferiority compared to the other conven-
tional approaches. A randomized controlled trial avoiding
selection bias and looking at time-to-progression as a pri-
mary endpoint may be the ideal tool for this.
Conclusions
The waiting interval after neoadjuvant CRT seems a valu-
able option to treat synchronous liver metastases from
rectal cancer with an acceptable safety profile. Many of
the drawbacks from classical delayed approaches may be
overcome without lengthening the overall treatment dur-
ation. More prospective long-term follow-up data are ne-
cessary to confirm its oncological efficacy.
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